Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Modified-Release Drug Delivery Systems: Rate-Programmed I01:22

Modified-Release Drug Delivery Systems: Rate-Programmed I

Rate-programmed drug delivery systems (DDS) are designed to release drugs at specific, controlled rates to maintain consistent therapeutic levels. These systems are categorized based on their release mechanisms, including dissolution-controlled DDS, diffusion-controlled DDS, and combined dissolution-diffusion-controlled DDS.In dissolution-controlled DDS, the release rate depends on the slow dissolution of the drug itself or the surrounding matrix. Drugs with inherently slow dissolution rates,...
Modified-Release Drug Delivery Systems: Classification01:23

Modified-Release Drug Delivery Systems: Classification

Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional reconfiguration of functional brain networks during childhood and adolescence: evaluating age and sex effect.

bioRxiv : the preprint server for biology·2026
Same author

Analysis of anticipatory postural adjustment characteristics in preschool children with different motor development profiles.

Gait & posture·2026
Same author

Targeting the Hedgehog Signaling Pathway in the Retina Using Quercetin-Loaded Lipid Nanoparticles for Myopia Control.

Translational vision science & technology·2026
Same author

Joint estimation of multiple graphical models for an fMRI study of brain connectivity networks.

Statistical methods in medical research·2026
Same author

Development and Interpretability Analysis of Near-Infrared Spectroscopy Models for Fat and Protein Prediction in Foxtail Millet [<i>Setaria italica</i> (L.) Beauv.].

Foods (Basel, Switzerland)·2026
Same author

Fragmentation effects on β-diversity: The role of abundance and intraspecific trait variation in shaping taxonomic, functional, and phylogenetic patterns.

Plant diversity·2026
Same journal

Superelastic Ti-Zr-Nb-Sn Thin Films Fabricated by Magnetron Sputtering: Biocompatibility and Bacterial Biofilm Formation Assessment for Orthopedic Applications.

Journal of biomedical materials research. Part A·2026
Same journal

Edible Sulfonated Soy Protein Microcarriers for Cultivated Meat Cell Expansion.

Journal of biomedical materials research. Part A·2026
Same journal

ROS-Responsive Quercetin Nanoparticles Improve the Prognosis of Traumatic Brain Injury by Inhibiting Aberrant Nrf2-Keap1 Signaling Pathway Activation.

Journal of biomedical materials research. Part A·2026
Same journal

Cellular Insights Into Proangiogenic Activation in Fibroblast and Endothelial Cells by Dual Drug-Loaded Emulsion Electrospun Nanofibers for Enhanced Tissue Regeneration.

Journal of biomedical materials research. Part A·2026
Same journal

Biomimetic Collagen Scaffolds Natural Cross-Linking Strategies via Transglutaminase and Methylglyoxal for Skin Repair.

Journal of biomedical materials research. Part A·2026
Same journal

Granular Hydrogel Composites for Noninvasive Optical Biosensing.

Journal of biomedical materials research. Part A·2026
See all related articles

Related Experiment Video

Updated: May 12, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

A pH-sensitive binary drug delivery system based on poly(caprolactone)-heparin conjugates.

Lin Ye1, Zemin Gao, Yu Zhou

  • 1Department of Materials Physics and Chemistry, School of Materials Science and Engineering, Beijing Institute of Technology, Beijing, 100081, China.

Journal of Biomedical Materials Research. Part A
|April 5, 2013
PubMed
Summary
This summary is machine-generated.

Novel core-shell nanoparticles effectively deliver dual chemotherapy drugs, paclitaxel and doxorubicin, for targeted cancer treatment. These nanoparticles show enhanced efficacy against cervical and breast cancer cells.

Keywords:
PCL-heparin conjugatebinary-drug delivery systemdoxorubicinpH sensitivepaclitaxel

More Related Videos

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Related Experiment Videos

Last Updated: May 12, 2026

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery
12:27

Polyelectrolyte Complex for Heparin Binding Domain Osteogenic Growth Factor Delivery

Published on: August 22, 2016

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

Area of Science:

  • Biomaterials Science
  • Nanotechnology
  • Drug Delivery Systems

Background:

  • Polycaprolactone (PCL) and heparin are biocompatible polymers with potential in drug delivery.
  • Developing effective delivery systems for binary anti-cancer drugs is crucial for improving therapeutic outcomes.
  • Nanoparticles offer advantages in drug encapsulation and targeted delivery.

Purpose of the Study:

  • To synthesize and characterize PCL-heparin core-shell nanoparticles for co-delivery of paclitaxel and doxorubicin.
  • To investigate the drug release kinetics and pH-dependent behavior of the loaded nanoparticles.
  • To evaluate the in vitro anti-cancer efficacy of the dual-drug loaded nanoparticles against cervical and breast cancer cells.

Main Methods:

  • Synthesis of PCL-heparin conjugates using EDC/NHS chemistry.
  • Self-assembly of nanoparticles with a core-shell structure (approx. 100 nm diameter).
  • Encapsulation of paclitaxel (lipophilic) in the core and doxorubicin (hydrophilic) in the shell via electrostatic interaction.
  • In vitro drug release studies under different pH conditions.
  • Cytotoxicity assays using Hela and MDA-MB-321 cancer cell lines.
  • Confocal laser scanning microscopy (CLSM) to observe intracellular drug localization.

Main Results:

  • PCL-heparin nanoparticles successfully encapsulated both paclitaxel and doxorubicin.
  • Drug release was sustained, with doxorubicin release being pH-dependent, favoring tumor environments.
  • Significant cytotoxicity was observed against Hela (cervical) and MDA-MB-321 (breast) cancer cells.
  • CLSM confirmed intracellular aggregation of both drugs within the nucleus of tumor cells.

Conclusions:

  • PCL-heparin core-shell nanoparticles provide a sequential, controlled release system for binary anti-cancer drugs.
  • The pH-responsive nature of doxorubicin release enhances targeted drug delivery to tumor cells.
  • These nanoparticles demonstrate potent anti-cancer activity and hold promise for treating cervical and breast cancers.